Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2000 Sep;50(3):227-35.
doi: 10.1046/j.1365-2125.2000.00256.x.

Influence of asimadoline, a new kappa-opioid receptor agonist, on tubular water absorption and vasopressin secretion in man

Affiliations
Clinical Trial

Influence of asimadoline, a new kappa-opioid receptor agonist, on tubular water absorption and vasopressin secretion in man

H J Kramer et al. Br J Clin Pharmacol. 2000 Sep.

Abstract

Aims: The purpose of the study was to investigate the effects of asimadoline, a new kappa-opioid agonist, on renal function and on hormones related to body fluid balance as well as its tolerability in healthy subjects.

Methods: In a placebo-controlled, randomised, double-blind crossover design we studied the effects of single oral doses of 1, 5, and 10 mg of asimadoline, in 24 healthy volunteers. Two hour control urine collections were followed by 2 h postdose urine collections and subsequently 2.5% saline was given i.v. at a rate of 0.3 ml min(-1) kg(-1) during another 2 h urine collection. Blood was obtained hourly. Arginine-vasopressin (AVP), atrial natriuretic peptide (alpha-hANP), endothelin (ET-1) and cAMP were determined by r.i.a. or ELISA.

Results: GC-MS measurements revealed Cmax values of asimadoline in plasma ranging from 18 ng ml(-1) at the 1 mg dose, 91 ng ml(-1) at the 5 mg dose, to 214 ng ml(-1) at the 10 mg dose after an average of 1.1-1.4 h. Without effects on blood pressure, heart rate, GFR or urine electrolyte excretion, urine volume increased after 1-2 h after administration of 5 and 10 mg asimadoline from 3.3+/-1.3 to 5.6+/-1.4 (P<0.05) and from 3.2 +/-1.6 to 5.5+/-2.2 ml min(-1) (P<0.01), respectively. CH2O rose from 0.2+/-1.5 to 2.0+/-1.6 (P<0.05) and from 0.6+/-1.6 to 3.0+/-1.6 ml min(-1) (P<0.01). Urinary excretion of AVP was suppressed only with the 10 mg dose from 46+/-23 to 25+/-15 fmol min(-1) (P<0.05) without and from 410+/-206 to 181+/-125 fmol min(-1) (P<0.05) with stimulation by 2.5% saline. Plasma AVP was suppressed only by the 10 mg dose of asimadoline in six of eight subjects during the 2.5% saline infusion. Changes in the alpha-hANP or ET-1 systems were not affected by asimadoline.

Conclusions: Asimadoline is diuretic in man after single doses of 5 or 10 mg probably through a direct effect at the renal tubular level. Suppression of AVP secretion was observed only at the highest dose level of 10 mg of asimadoline.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Semilogarithmic plot of plasma concentrations of asimadoline during 24 h after oral administration of 1 (▪), 5 (bull;), and 10 mg (▴) asimadoline in each group of eight healthy subjects. Data are given as means ± s.e.mean.
Figure 2
Figure 2
Urine volume during the 2 h control period (C; −2–0 h), the 2 h postdose collection period (0–2 h) and during the subsequent 2 h (2–4 h) of 2.5% saline infusion after oral administration of single doses of 5 and 10 mg of asimadoline (hatched column) or placebo (open column) in each group of eight healthy subjects. Data are given as means ± s.e.mean; *P < 0.05, **P < 0.01.
Figure 3
Figure 3
Free-water clearance during the 2 h control period (C; −2–0), the 2 h postdose collection period (0–2 h) and during the subsequent 2 h (2–4 h) of 2.5% saline infusion after oral administration of single doses of 5 and 10 mg of asimadoline (hatched colum) or placebo (open column) in each group of eight healthy subjects. Data are given as means ± s.e.mean; *P < 0.05, **P < 0.01.
Figure 4
Figure 4
Urinary AVP excretion during the 2 h control period (C; −2–0 h), the 2 h postdose collection period (0–2 h) and during the subsequent 2 h (2–4 h) of 2.5% saline infusion after oral administration of a single dose of 10 mg asimadoline or placebo in each group of eight healthy subjects. Data are given as means ± s.e.mean; *P < 0.05 asimadoline vs placebo during 2.5% saline infusion.

References

    1. Miller M. Inhibition of ADH release in the rat by narcotic antagonists. Neuroendocrinology. 1975;19:241–251. - PubMed
    1. Nutt JG, Jasinski DR. Diuretic action of the narcotic antagonist oxilorphan. Clin Pharmacol Ther. 1974;15:361–367. - PubMed
    1. Dykstra LA, Gmerek DE, Winger G, Woods JH. k-opioids in rhesus monkeys. I. Diuresis, sedation, analgesia and discriminative stimulus effects. J Pharmacol Exp Ther. 1987;242:413–420. - PubMed
    1. Slizgi GR, Ludens JH. Studies on the nature and mechanism of the diuretic activity of the opioid analgesic ethylketocycloazocine. J Pharmacol Exp Ther. 1982;220:585–591. - PubMed
    1. Slizgi GR, Taylor CJ, Ludens JH. Effects of the highly selective k- opioid U-50,488 on renal function in the anesthetized dog. J Pharmacol Exp Ther. 1984;230:641–645. - PubMed

Publication types

MeSH terms